Important note:
Unless otherwise indicated, this policy will apply to all lines of business.
Even though this policy may indicate that a particular service or supply may be considered medically necessary and thus covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit plan contains its own specific provisions for coverage and exclusions. Not all benefits that are determined to be medically necessary will be covered under the terms of your benefit plan. You need to consult the Evidence of Coverage (EOC) or Summary Plan Description (SPD) to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and your plan of benefits, the provisions of your benefits plan will govern. However, applicable state mandates will take precedence with respect to fully insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, Federal mandates will apply to all plans. With respect to Medicare-linked plan members, this policy will apply unless there are Medicare policies that provide differing coverage rules, in which case Medicare coverage rules supersede guidelines in this policy. Medicare-linked plan policies will only apply to benefits paid for under Medicare rules, and not to any other health benefit plan benefits. CMS's Coverage Issues Manual can be found on the CMS website. Similarly, for Medicaid-linked plans, the Texas Medicaid Provider Procedures Manual (TMPPM) supersedes coverage guidelines in this policy where applicable.

SERVICE: Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Other Conditions Associated with Increased Bone Turnover

PRIOR AUTHORIZATION: Not applicable and not required for Medicare lines of business.

POLICY:
For Medicare lines of business, collagen crosslink testing may be medically necessary especially during the start of anti-resorptive therapy.

For all other lines of business, SWHP considers the use of bone turnover markers for the diagnosis and management of osteoporosis and other conditions associated with increased bone turnover to be experimental and investigational and not medically necessary.

OVERVIEW: After cessation of growth, bone is in a constant state of remodeling, (or turnover). Two basic types of biochemical markers can assess bone turnover:
- Markers of bone resorption, and
- Markers of bone formation.

Additionally, they can be categorized into two groups:
- Markers that measure substances released by osteoblasts and osteoclasts, and
- Markers that measure substances produced during the formation or breakdown of a collagen, a protein found in bone.

Commercially available tests are available to assess some of these markers in urine and/or serum by High Performance Liquid Chromatography (HPLC) or immunoassay. Assessment of bone turnover markers is proposed to supplement bone mineral density (BMD) measurement in the diagnosis of osteoporosis, and aid in treatment decisions. Bone turnover markers could also
potentially be used to evaluate treatment effectiveness before changes in BMD can be observed.

Bone turnover is correlated with the presence of certain biochemical markers in serum and/or urine that result from net activity in bone throughout the entire skeleton. In contrast, bone mass measurements (e.g., bone density studies) and radiographs (e.g., x-rays) provide a static picture of a specific skeletal site.

Collagen cross links are generally reliable markers of bone resorption because they are stable in serum and urine. These markers links bind three molecules of collagen in the bone and are released from the bone matrix after resorption, either free or bound to the N- or C- telopeptide of collagen. Collagen cross links may be detected using either high-pressure liquid chromatography (HPLC)-fluorometric assays (Pyr, D-Pyr), or immunoassays (Pyr, D-Pyr, CTx, NTx). In addition to collagen cross links, ALP is a commonly used marker due to its ease of measurement; however, it lacks sensitivity and specificity for detecting osteoporosis since only about half of the ALP activity is derived from bone. Bone-specific alkaline phosphatase (B-ALP) is a better marker of bone formation than ALP. Serum osteocalcin is a small noncollagenous protein that is a product of osteoblasts and thus increased levels reflect bone formation. Tartrate-resistant acid phosphatase (TRAP) is produced by osteoclasts; it is thought to be active in bone matrix degradation.

The literature suggests that alternative measures of bone strength have the potential to assess individual responses to treatment or identify individuals at high risk of future fracture, thereby potentially altering clinical management. However, there is insufficient evidence that current methods for measuring bone turnover markers are sufficiently sensitive to reliably determine individual treatment responses. Measurement of bone turnover has not been shown to improve health outcomes.

**MANDATES:** None

**CMS:** NCD 190.19 (2004)

Indications: “Generally speaking, collagen crosslink testing is useful mostly in “fast losers” of bone. The age when these bone markers can help direct therapy is often pre-Medicare. By the time a fast loser of bone reaches age 65, she will most likely have been stabilized by appropriate therapy or have lost so much bone mass that further testing is useless. Coverage for bone marker assays may be established, however, for younger Medicare beneficiaries and for those men and women who might become fast losers because of some other therapy such as glucocorticoids. Safeguards should be incorporated to prevent excessive use of tests in patients for whom they have no clinical relevance.

Collagen crosslinks testing is used to:
- Identify individuals with elevated bone resorption, who have osteoporosis in whom response to treatment is being monitored.
### Limitations and Frequency:

“Because of significant specimen to specimen collagen crosslink physiologic variability (15-20%), current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about 3 months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the 3-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated 3 months after the initiation of new therapy.”

### CODES:

**Important note:**

**CODES:** Due to the wide range of applicable diagnosis codes and potential changes to codes, an inclusive list may not be presented, but the following codes may apply. Inclusion of a code in this section does not guarantee that it will be reimbursed, and patient must meet the criteria set forth in the policy language.

<table>
<thead>
<tr>
<th>CPT Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>82523</td>
<td>Collagen cross links, any method (Medicare lines of business ONLY)</td>
</tr>
<tr>
<td>82523</td>
<td>Collagen cross links, any method</td>
</tr>
<tr>
<td>82607</td>
<td>Cyanocobalamin (Vitamin B-12)</td>
</tr>
<tr>
<td>82608</td>
<td>Cyanocobalamin (Vitamin B-12); unsaturated binding capacity</td>
</tr>
<tr>
<td>83090</td>
<td>Homocysteine</td>
</tr>
<tr>
<td>83937</td>
<td>Osteocalcin (bone g1a protein)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10 codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M80.00X+</td>
<td>M81.8 Age-related osteoporosis with or without current pathological fracture</td>
</tr>
<tr>
<td>N25.0</td>
<td>Renal osteodystrophy [for persons receiving serotonergic anti-depressants]</td>
</tr>
<tr>
<td>Q78.0</td>
<td>Osteogenesis imperfecta</td>
</tr>
<tr>
<td>Z13.820</td>
<td>Encounter for screening for osteoporosis</td>
</tr>
</tbody>
</table>

### POLICY HISTORY:

<table>
<thead>
<tr>
<th>Status</th>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>1/6/2010</td>
<td>New policy</td>
</tr>
<tr>
<td>Reviewed</td>
<td>10/25/2012</td>
<td>Reviewed.</td>
</tr>
<tr>
<td>Reviewed</td>
<td>10/3/2013</td>
<td>Minor changes. Added NCD from 2003 190.19 for reference</td>
</tr>
<tr>
<td>Reviewed</td>
<td>07/24/2014</td>
<td>No changes</td>
</tr>
<tr>
<td>Reviewed</td>
<td>08/11/2015</td>
<td>No changes</td>
</tr>
<tr>
<td>Reviewed</td>
<td>08/18/2016</td>
<td>No changes</td>
</tr>
</tbody>
</table>
MEDICAL COVERAGE POLICY

SERVICE: Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Other Conditions Associated with Increased Bone Turnover

Policy Number: 030
Effective Date: 11/01/2019
Last Review: 08/22/2019
Next Review Date: 08/22/2020

Reviewed 08/08/2017 No significant changes
Reviewed 05/29/2018 No significant changes
Reviewed 08/22/2019 No significant changes. Added ICD-10 codes

REFERENCES:
The following scientific references were utilized in the formulation of this medical policy. SWHP will continue to review clinical evidence related to this policy and may modify it at a later date based upon the evolution of the published clinical evidence. Should additional scientific studies become available and they are not included in the list, please forward the reference(s) to SWHP so the information can be reviewed by the Medical Coverage Policy Committee (MCPC) and the Quality Improvement Committee (QIC) to determine if a modification of the policy is in order.


